Arrowhead Announces Exclusive Worldwide License Agreement With Madrigal For ARO-PNPLA3, Clinical Stage RNAi Therapeutic To Reduce Liver Expression Of PNPLA3 As Potential Treatment For Metabolic Dysfunction-Associated Steatohepatitis
Benzinga Newsdesk 6 months ago
News
- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH- Phase 1 data published in The New England Journal of Medicine demonstrated a 46%
- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH
- Phase 1 data published in The New England Journal of Medicine demonstrated a 46% reduction in liver fat in homozygous patients and a well-tolerated safety profile
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ:MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH).